Nocionix,Inc. — SEC Form D Filing
Nocionix,Inc. filed an SEC Form D on November 4, 2026, reporting $2.70M raised in Other Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 4, 2026
- Amount reported
- $2.70M
- Round stage
- Seed funding stage based on the $2.7 million raised through convertible notes for early clinical development.
- Industry
- Other Health Care
- Website
- https://www.nocionix.com
What the company does
Securities: Debt, Convertible notes and equity issuable upon any conversion thereof. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Chronic pain and neurological conditions lack targeted, non-addictive therapies that safely attenuate pain signals without systemic side effects.
Solution
Nocionix develops novel therapeutics targeting peripheral nociceptive pathways to treat severe pain conditions.
Why now
Regulatory mandates prioritizing non-opioid pain treatments combined with advances in targeted nociceptor pharmacology enable safer pain management solutions.
Source: SEC EDGAR Form D filing